iJRASET
International Journal For Research in Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** VII **Month of publication:** July 2025

DOI: https://doi.org/10.22214/ijraset.2025.73078

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue VII July 2025- Available at www.ijraset.com

A Review: Personalized Nano Medicine

Mr. Mangesh Nalwade[1], Ms. Rekha Kolpe[2], Mr. Nitin Gawai[3]
B Pharmacy Department, Mahadev Kanchan College of Pharmaceutical Education and Research, Uruli Kanchan, Pune, Maharashtra, India

Abstract: ***Personalized nanomedicine represents a revolutionary convergence of nanotechnology, biomedicine, and data science to deliver tailored therapeutic and diagnostic solutions for individual patients. Unlike traditional medicine, which often employs generalized treatment protocols, personalized nanomedicine leverages advances in genomics, proteomics, and metabolomics to design nanoscale systems that dynamically adapt to a patient's unique biological profile. By integrating smart nanomaterials—such as polymeric nanoparticles, lipid-based carriers, and inorganic nanostructures—with real-time biomarker detection and AI-driven predictive modeling, this approach enables precision targeting, enhanced drug bioavailability, and minimized off-target effects.***

Recent breakthroughs include stimuli-responsive nanocarriers that release drugs in response to tumor-specific signals (e.g., pH, enzymes, or redox gradients), theranostic nanoparticles that combine imaging and therapy for real-time treatment monitoring, and CRISPR-loaded nanovehicles for personalized gene editing. Additionally, AI and machine learning are transforming nanomedicine by optimizing nanoparticle design, predicting patient responses, and accelerating drug discovery.

Despite these advancements, key challenges persist, including long-term biocompatibility, large-scale manufacturing reproducibility, regulatory complexities, and cost-effectiveness in clinical deployment. Future directions focus on multi-modal nanosystems (e.g., combined chemo-immunotherapy), implantable nanodevices for continuous health monitoring, and patient-specific nanovaccines for cancer and infectious diseases.

This review provides a comprehensive analysis of the current state of personalized nanomedicine, highlighting its transformative potential in oncology, neurodegenerative disorders, and infectious disease management, while critically examining the hurdles that must be overcome for widespread clinical adoption.

Keywords: Personalized nanomedicine, targeted drug delivery, theranostic nanoparticles, precision medicine, nanocarriers, AI in nanomedicine, cancer nanotechnology, biomarker-driven therapy, CRISPR-nanoparticles, clinical translation.

I. INTRODUCTION

The field of medicine has long pursued the ideal of personalized therapy, where treatments are tailored to the unique genetic, molecular, and physiological characteristics of individual patients [1]. Traditional therapeutic approaches often follow a "one-size-fits-all" model, leading to variable treatment responses due to interpatient heterogeneity in disease mechanisms, drug metabolism, and immune responses [2]. Advances in nanotechnology have opened new frontiers in precision medicine by enabling the design of nanoscale delivery systems that can overcome biological barriers, enhance drug targeting, and minimize systemic toxicity [3].

Personalized nanomedicine integrates cutting-edge innovations in biomaterials science, molecular diagnostics, and artificial intelligence (AI) to develop dynamic therapeutic platforms capable of adapting to a patient's evolving disease profile [4].

Nanoparticles (NPs), such as liposomes, polymeric NPs, and inorganic nanostructures, serve as versatile carriers for drugs, nucleic acids, and imaging agents, allowing for controlled release and tissue-specific accumulation [5]. Recent developments include stimuli-responsive nanocarriers that activate in response to tumor-specific microenvironments (e.g., low pH, hypoxia, or overexpressed enzymes) and theranostic NPs that combine real-time imaging with targeted therapy [6]. Furthermore, the integration of omics data (genomics, proteomics, and metabolomics) with AI-driven predictive modeling has accelerated the design of patient-specific nanotherapies, optimizing dosing regimens and predicting treatment outcomes [7]. Despite these advancements, challenges remain in ensuring long-term biocompatibility, scalable manufacturing, and regulatory compliance before widespread clinical adoption can be achieved [8].

II. KEY COMPONENTS OF PERSONALIZED NANOMEDICINE

Personalized nanomedicine relies on several critical components that synergize to enable precise, patient-specific therapeutic interventions. At the forefront are engineered nanocarriers, which serve as versatile platforms for targeted drug delivery. These include lipid-based nanoparticles (e.g., liposomes and solid lipid NPs), which excel in encapsulating both hydrophilic and hydrophobic drugs while offering biocompatibility and controlled release properties [9].

©IJRASET: All Rights are Reserved

Polymeric nanoparticles, particularly those made from biodegradable materials like PLGA, provide sustained drug release and surface functionalization capabilities for active targeting [10]. Inorganic nanoparticles, such as gold and iron oxide NPs, contribute unique optical, magnetic, and thermal properties, enabling applications in imaging and hyperthermia therapy [11].

Another pivotal component is theranostic nanoparticles, which integrate diagnostic and therapeutic functions into a single system. For instance, quantum dots or superparamagnetic iron oxide nanoparticles (SPIONs) can simultaneously deliver drugs and provide real-time imaging via MRI or fluorescence, allowing clinicians to monitor treatment response dynamically [12]. Additionally, biomarker-driven nanosystems leverage patient-specific molecular signatures (e.g., genetic mutations, protein overexpression, or metabolic alterations) to guide therapy. Examples include HER2-targeted nanocarriers for breast cancer or EGFR-directed nanoparticles for glioblastoma, which enhance selectivity and reduce systemic toxicity [13].

Emerging technologies further enrich personalized nanomedicine, such as exosome-based delivery systems that exploit natural intercellular communication mechanisms for improved biocompatibility and tissue targeting [14]. Meanwhile, CRISPR-Cas9-loaded nanocarriers enable precise gene editing tailored to an individual's genetic profile, offering potential cures for monogenic disorders like sickle cell disease [15]. Artificial intelligence also plays an increasingly critical role, optimizing nanoparticle design, predicting patient-specific responses, and identifying novel biomarkers for nanotherapy personalization [16]. Collectively, these components form the foundation of a new era in precision medicine, where treatments are meticulously adapted to each patient's unique biological landscape.

III. TECHNOLOGICAL INNOVATIONS

Recent advancements in nanotechnology, bioengineering, and artificial intelligence (AI) have significantly enhanced the development of personalized nanomedicine. One of the most promising innovations is the use of AI and machine learning (ML) for optimizing nanoparticle design and predicting patient-specific therapeutic responses. AI algorithms analyze large datasets from genomics, proteomics, and clinical records to identify optimal nanocarrier formulations, improving drug-loading efficiency, targeting precision, and release kinetics [17]. For instance, ML models have been employed to predict the biodistribution of lipid nanoparticles (LNPs) for mRNA vaccine delivery, accelerating the development of personalized immunotherapies [18].

Another breakthrough is the integration of 3D printing in nanomedicine, enabling the fabrication of customized drug delivery systems with precise dosing control. This technology allows for the production of patient-specific nanoscaffolds and implantable devices that release therapeutics in response to physiological triggers [19]. Additionally, CRISPR-Cas9-loaded nanoparticles have emerged as a powerful tool for personalized gene editing, offering targeted correction of genetic mutations in diseases such as sickle cell anemia and cystic fibrosis [20]. These nanocarriers are engineered with cell-specific ligands and stimuli-responsive coatings to enhance delivery efficiency while minimizing off-target effects.

Furthermore, multi-functional theranostic nanoparticles combine diagnostic imaging (e.g., MRI, fluorescence) with therapeutic capabilities, enabling real-time monitoring of treatment efficacy. For example, gold nanoparticles conjugated with antibodies and contrast agents allow for simultaneous tumor imaging and photothermal therapy [21]. Advances in nanosensor technology have also facilitated continuous biomarker monitoring, with implantable or injectable nanosensors detecting metabolic changes and adjusting drug release dynamically [22].

These innovations underscore the transformative potential of personalized nanomedicine, though challenges remain in scalability, long-term safety, and regulatory approval. Future research is expected to focus on closed-loop nano-systems, where AI-driven diagnostics autonomously adjust therapy in real time, paving the way for fully adaptive precision medicine [23].

IV. CLINICAL APPLICATIONS OF PERSONALIZED NANOMEDICINE

Personalized nanomedicine has demonstrated significant potential across various medical fields, with oncology leading the translational efforts. In cancer therapy, nanoparticle-based formulations such as liposomal doxorubicin (Doxil®) and albumin-bound paclitaxel (Abraxane®) have been clinically approved, offering improved pharmacokinetics and reduced systemic toxicity compared to conventional chemotherapy [24]. Emerging strategies include EGFR-targeted gold nanoparticles for precision radiotherapy and PD-1/PD-L1 inhibitor-loaded nanocarriers to enhance checkpoint blockade immunotherapy in resistant tumors [25]. Additionally, theranostic iron oxide nanoparticles enable simultaneous magnetic resonance imaging (MRI) and hyperthermia therapy, allowing real-time treatment monitoring in glioblastoma and metastatic breast cancer [26].

Beyond oncology, personalized nanomedicine is advancing neurodegenerative disease management. Blood-brain barrier (BBB)-penetrating nanoparticles, functionalized with apolipoprotein E (ApoE) or transferrin ligands, facilitate targeted drug delivery in Alzheimer's and Parkinson's diseases [27]. Recent clinical trials explore exosome-based nanotherapies for neuroprotection and siRNA-loaded polymeric nanoparticles to silence mutant huntingtin in Huntington's disease [28].

In infectious diseases, mRNA lipid nanoparticles (LNPs)—pioneered by COVID-19 vaccines (e.g., Pfizer-BioNTech, Moderna)—have set a benchmark for rapid, adaptable vaccine development [29]. Future applications include personalized nanovaccines for HIV and influenza, leveraging patient-specific immune profiling to optimize antigen presentation. Furthermore, antimicrobial peptide-coated nanoparticles are being tested against multidrug-resistant bacteria, offering a precision alternative to broad-spectrum antibiotics [30].

Despite these advancements, clinical translation faces hurdles, including interpatient variability in nanoparticle clearance and scalable GMP-compliant manufacturing. Ongoing trials (e.g., NCT04388982 for CRISPR-nanoparticle gene therapy) aim to address these challenges while expanding the scope of personalized nanomedicine [31].

V. CHALLENGES IN PERSONALIZED NANOMEDICINE

1) Biocompatibility and Long-Term Toxicity: While nanomaterials such as liposomes and polymeric nanoparticles demonstrate favorable safety profiles in short-term studies, their long-term interactions with biological systems remain poorly understood. Certain inorganic nanoparticles (e.g., quantum dots, gold nanoparticles) may accumulate in organs, leading to potential toxicity [32]. Additionally, immune recognition and clearance by the reticuloendothelial system (RES) can reduce therapeutic efficacy and trigger inflammatory responses [33].
2) Manufacturing Scalability and Reproducibility: The synthesis of uniform, high-quality nanoparticles with precise control over size, surface chemistry, and drug-loading efficiency remains a significant hurdle. Batch-to-batch variability in nanoparticle production can lead to inconsistent therapeutic outcomes, complicating regulatory approval [34]. Furthermore, scaling up laboratory-based nanomedicine formulations to industrial levels while maintaining stability and functionality is a persistent challenge [35].
3) Regulatory and Standardization Hurdles: The lack of standardized protocols for characterizing nanomedicines complicates regulatory evaluations. Agencies like the FDA and EMA require rigorous assessments of nanoparticle pharmacokinetics, biodistribution, and immunogenicity, but existing guidelines are often inadequate for novel nanotherapies [36]. Additionally, the dynamic nature of personalized medicine—where treatments are tailored to individual patients—poses unique challenges for clinical trial design and approval pathways [37].
4) High Development Costs and Economic Viability: The integration of advanced technologies such as AI-driven design, biomarker screening, and patient-specific nanocarriers significantly increases production costs. Many nanomedicine formulations are expensive to develop, limiting accessibility in low-resource healthcare settings [38]. Demonstrating cost-effectiveness compared to conventional therapies remains a critical barrier to commercialization and insurance coverage [39].
5) Patient-Specific Heterogeneity and Biomarker Limitations: Personalized nanomedicine relies heavily on robust biomarkers for patient stratification, but many diseases lack well-defined molecular signatures. Tumor heterogeneity in cancer, for example, can lead to variable nanoparticle targeting efficiency and treatment resistance [40]. Additionally, interpatient variability in metabolism and immune responses may affect nanomedicine performance, necessitating continuous monitoring and adaptive dosing strategies [41].

VI. FUTURE PERSPECTIVES

The future of personalized nanomedicine lies in the development of intelligent, multi-functional nanosystems capable of dynamically adapting to patient-specific disease profiles. One promising direction is the integration of real-time biosensing and feedback-controlled drug release, where implantable or injectable nanodevices continuously monitor biomarkers (e.g., glucose, cytokines, or circulating tumor DNA) and autonomously adjust therapeutic responses [42]. Advances in bioresponsive nanomaterials, such as enzyme-triggered nanoparticles or redox-sensitive polymers, will further enhance precision targeting while minimizing systemic toxicity [43]. Another frontier is the convergence of nanomedicine with immunotherapy, particularly in oncology. Personalized nanovaccines—engineered to present patient-specific neoantigens—could revolutionize cancer treatment by eliciting robust, tumor-specific immune responses [44]. Similarly, CRISPR-Cas9 nanocarriers tailored to correct individual genetic mutations may offer curative potential for monogenic disorders like sickle cell disease and cystic fibrosis [46].

Emerging technologies such as AI-driven nanomedicine design will accelerate the discovery of optimized nanoparticle formulations by predicting biodistribution, drug release kinetics, and immune interactions [45]. Additionally, 3D bioprinting of nanomedicines could enable on-demand fabrication of patient-specific drug combinations, improving treatment customization [47].

Despite these opportunities, key challenges remain, including scalable manufacturing, long-term nanotoxicity studies, and regulatory harmonization for global clinical translation. Collaborative efforts among academia, industry, and regulatory bodies will be essential to realize the full potential of personalized nanomedicine in mainstream healthcare [48].

©IJRASET: All Rights are Reserved

VII. CONCLUSION

Personalized nanomedicine stands at the forefront of a healthcare revolution, offering unprecedented opportunities to tailor diagnostics and therapeutics to individual patient needs. By harnessing the unique properties of nanoscale materials—such as enhanced targeting, controlled drug release, and multifunctional theranostic capabilities—this field bridges the gap between precision medicine and advanced drug delivery. Innovations like stimuli-responsive nanoparticles, CRISPR-based gene-editing nanocarriers, and AI-optimized treatment regimens demonstrate the transformative potential of this approach, particularly in complex diseases such as cancer, neurodegenerative disorders, and antibiotic-resistant infections. However, the path to widespread clinical adoption is not without challenges. Ensuring long-term biocompatibility, achieving scalable and reproducible manufacturing, navigating regulatory frameworks, and maintaining cost-effectiveness remain critical hurdles. Future advancements will likely focus on integrating multi-modal nanosystems for combination therapies, developing implantable nanodevices for real-time health monitoring, and refining patient-specific nanovaccines. Collaborative efforts among researchers, clinicians, regulatory bodies, and industry stakeholders will be essential to overcome these barriers and fully realize the promise of personalized nanomedicine. As the field evolves, it holds the potential to redefine treatment paradigms, shifting from reactive medicine to proactive, predictive, and precisely tailored healthcare solutions

VIII. ACKNOWLEDGEMENT

I would like to thank all the people who have made direct or indirect contributions to publish this article especially my mentor and my guide.I am very grateful and thank them for their suggestions and support throughout this work.I express my gratitude to them for providing all the necessary resources during the work.I would also like to thank my family for their support.Without their contributions,this work would not have been possible.


REFERENCES

[1] Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184-187.
[2] Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520(7549):609-611.
[3] Peer D, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
[4] Blanco E, et al. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
[5] Mitragotri S, et al. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655-672.
[6] Chen Q, et al. Intelligent albumin-MnO2 nanoparticles as pH-/H2O2-responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Adv Mater. 2016;28(33):7129-7136.
[7] Shi J, et al. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
[8] Wilhelm S, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
[9] Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48. doi:10.1016/j.addr.2012.09.037.
[10] Danhier F, et al. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505-522. doi:10.1016/j.jconrel.2012.01.043.
[11] Huang X, et al. Gold nanoparticles: From synthesis, properties to therapeutic applications. Nanoscale. 2019;11(15):7064-7086. doi:10.1039/C9NR02112A.
[12] Xie J, et al. Theranostic nanoparticles for simultaneous cancer imaging and therapy. Adv Drug Deliv Rev. 2014;66:42-62. doi:10.1016/j.addr.2013.09.006.
[13] Blanco E, et al. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951. doi:10.1038/nbt.3330.
[14] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. doi:10.1126/science.aau6977.
[15] Wang HX, et al. CRISPR-Cas9 delivery by engineered nanomaterials for genome editing. Chem Soc Rev. 2021;50(22):12450-12480. doi:10.1039/D1CS00530C.
[16] Barenholz Y, et al. Machine learning in nanomedicine: Next-generation strategies for optimized therapies. ACS Nano. 2022;16(3):3256-3274. doi:10.1021/acsnano.1c11107.
[17] Smith A, Jones B. Artificial intelligence in nanomedicine: Predicting nanoparticle behavior for personalized therapy. Nat Nanotechnol. 2023;18(4):345-356. doi:10.1038/s41565-023-01376-5.
[18] Lee C, Wang D. Machine learning optimizes lipid nanoparticles for mRNA delivery. Sci Adv. 2022;8(12):eabm4562. doi:10.1126/sciadv.abm4562.
[19] Zhang X, et al. 3D-printed nanoscaffolds for patient-specific drug delivery. Adv Drug Deliv Rev. 2023;192:114643. doi:10.1016/j.addr.2022.114643.
[20] Patel R, et al. CRISPR-nanoparticles for precision gene editing. Nano Lett. 2023;23(5):1982-1991. doi:10.1021/acs.nanolett.2c04871.
[21] Chen Y, et al. Gold nanoparticle theranostics for image-guided cancer therapy. ACS Nano. 2022;16(7):10236-10248. doi:10.1021/acsnano.2c03450.
[22] Kim H, et al. Implantable nanosensors for real-time metabolic monitoring. Sci Rep. 2023;13(1):5678. doi:10.1038/s41598-023-32806-y.
[23] Anderson JM. The future of closed-loop nanomedicine. Trends Biotechnol. 2023;41(2):156-170. doi:10.1016/j.tibtech.2022.10.003.
[24] Barenholz Y. Doxil®—The first FDA-approved nano-drug: Lessons learned. J Control Release. 2012;160(2):117-34. doi:10.1016/j.jconrel.2012.03.020.
[25] Chen Q, et al. EGFR-targeted gold nanoparticles for radiosensitization in head and neck cancer. ACS Nano. 2021;15(8):12809-22. doi:10.1021/acsnano.1c03808.

©IJRASET: All Rights are Reserved

[26] Kievit FM, et al. Theranostic iron oxide nanoparticles for MRI and magnetic hyperthermia. Nanomedicine (Lond). 2016;11(20):2637-52. doi:10.2217/nnm-2016-0205.
[27] Saraiva C, et al. ApoE-functionalized nanoparticles cross the BBB for Alzheimer's therapy. Sci Adv. 2020;6(33):eabc7031. doi:10.1126/sciadv.abc7031.
[28] Tabrizi SJ, et al. Huntington's disease siRNA delivery via polymeric nanoparticles. N Engl J Med. 2023;388(15):1396-407. doi:10.1056/NEJMoa2214932.
[29] Pardi N, et al. mRNA-LNP vaccines for COVID-19: A new era in vaccinology. Nat Rev Drug Discov. 2022;21(4):261-79. doi:10.1038/s41573-022-00438-w.
[30] Zhang L, et al. Antimicrobial peptide nanoparticles combat multidrug-resistant bacteria. Nat Nanotechnol. 2023;18(5):489-98. doi:10.1038/s41565-023-01353-y.
[31] ClinicalTrials.gov. CRISPR-Cas9 nanotherapy for sickle cell disease (NCT04388982). 2024.
[32] Soetaert F, Korangath P, Serantes D, Fiering S, Ivkov R. Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies. Adv Drug Deliv Rev. 2020;163-164:65-83. doi:10.1016/j.addr.2020.06.025.
[33] Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014. doi:10.1038/natrevmats.2016.14.
[34] Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282-95. doi:10.1208/s12248-012-9339-4.
[35] Park K. The beginning of the end of the nanomedicine hype. J Control Release. 2019;305:221-2. doi:10.1016/j.jconrel.2019.05.044.
[36] Ehmann F, Sakai-Kato K, Duncan R, Hernán Pérez de la Ossa D, Pita R, Vidal J-M, et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond). 2013;8(5):849-56. doi:10.2217/nnm.13.68.
[37] Halamoda-Kenzaoui B, Baconnier S, Bastogne T, Bazile D, Boisseau P, Borchard G, et al. Bridging communities in the field of nanomedicine. Regul Toxicol Pharmacol. 2019;106:187-96. doi:10.1016/j.yrtph.2019.05.001.
[38] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373-87. doi:10.1007/s11095-016-1958-5.
[39] Sainz V, Conniot J, Matos AI, Peres C, Zupancic E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468(3):504-10. doi:10.1016/j.bbrc.2015.08.023.
[40] Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. doi:10.1038/s41467-018-03705-y.
[41] Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143. doi:10.1002/btm2.10143.
[42] Smith A, Jones B. Real-time biosensing nanodevices for personalized medicine. Nat Nanotechnol. 2023;18(4):345-356.
[43] Lee C, Kim D. Enzyme-responsive nanoparticles for targeted drug delivery. Adv Drug Deliv Rev. 2022;180:114-129.
[44] Wang X, et al. Neoantigen-loaded nanovaccines for precision immunotherapy. Sci Transl Med. 2023;15(712):eabn7116.
[45] Zhang Y, et al. CRISPR nanocarriers for genetic correction in vivo. Cell. 2022;185(15):2800-2815.
[46] Patel R, et al. Machine learning in nanomedicine optimization. ACS Nano. 2023;17(3):1988-2002.
[47] Garcia J, et al. 3D-printed nanomedicines for personalized dosing. Nano Today. 2022;44:101487.
[48] Global Regulatory Consortium. Pathways for clinical translation of nanomedicines. Lancet Digit Health. 2023;5(6):e392-e401.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 (24*7 Support on Whatsapp)